Topic hub
GLP-1: starting, stopping and restarting
Who considers a GLP-1, what makes them start, what makes a past user stop, and what would bring them back.
What did the panels say about glp-1: starting, stopping and restarting?
- #
89%
89% give strong praise to Diet-and-Exercise Jordan, against 1% for Medication Jordan, who lost the same 60 pounds (separate samples) — 89% strongly praise weight lost through diet and exercise, against 1% when the same weight is lost on medication
base 200
- #
67.5%
67.5% of past GLP-1 users rely most on eating less or eating differently on their own to keep the weight off, and 17.5% on exercise or a fitness routine. — After stopping a GLP-1, 67.5% keep the weight off by changing their diet on their own and 17.5% by fitness; a $29 maintenance program would draw 62.0%, a $149 one 19.3%
base 166
- #
65.5%
65.5% of GLP-1 considerers would turn to diet, exercise or a program (34.5%) or put treatment off (30.9%) if their plan dropped weight-loss coverage; 11.5% would pay a drug maker's cash price. — When a plan drops GLP-1 weight-loss coverage, 65.5% of considerers turn away from medicine, not to cash, yet 80.6% would switch plans to keep it
base 139
- #
35.3%
35.3% of US past GLP-1 users say side effects were the main reason they stopped, and 31.2% the monthly cost or losing insurance coverage — Why past GLP-1 users stop, and what brings them back: side effects (35.3%) and cost (31.2%) lead, and the fix must match the reason, with 94.3% of cost quitters wanting coverage under $50 and 60.0% of side-effect quitters a lower dose
base 170
- #
37.5%
37.5% of weekly GLP-1 injection users (75 of 200) would be likely to switch to a once-daily pill at the same price and the same weight loss; 55.0% would be very unlikely to. — GLP-1 pill or injection? 37.5% of weekly injection users would switch at the same price, and a smaller weight loss cuts that to 17.0%
base 200
What has Brox published on glp-1: starting, stopping and restarting?Newest first
-
89% strongly praise weight lost through diet and exercise, against 1% when the same weight is lost on medication
89% 89% give strong praise to Diet-and-Exercise Jordan, against 1% for Medication Jordan, who lost the same 60 pounds (separate samples) (base 200)
Read -
After stopping a GLP-1, 67.5% keep the weight off by changing their diet on their own and 17.5% by fitness; a $29 maintenance program would draw 62.0%, a $149 one 19.3%
67.5% 67.5% of past GLP-1 users rely most on eating less or eating differently on their own to keep the weight off, and 17.5% on exercise or a fitness routine. (base 166)
Read -
When a plan drops GLP-1 weight-loss coverage, 65.5% of considerers turn away from medicine, not to cash, yet 80.6% would switch plans to keep it
65.5% 65.5% of GLP-1 considerers would turn to diet, exercise or a program (34.5%) or put treatment off (30.9%) if their plan dropped weight-loss coverage; 11.5% would pay a drug maker's cash price. (base 139)
Read -
Why past GLP-1 users stop, and what brings them back: side effects (35.3%) and cost (31.2%) lead, and the fix must match the reason, with 94.3% of cost quitters wanting coverage under $50 and 60.0% of side-effect quitters a lower dose
35.3% 35.3% of US past GLP-1 users say side effects were the main reason they stopped, and 31.2% the monthly cost or losing insurance coverage (base 170)
Read -
GLP-1 pill or injection? 37.5% of weekly injection users would switch at the same price, and a smaller weight loss cuts that to 17.0%
37.5% 37.5% of weekly GLP-1 injection users (75 of 200) would be likely to switch to a once-daily pill at the same price and the same weight loss; 55.0% would be very unlikely to. (base 200)
Read -
Past GLP-1 users would restart at $99 a month (59.1%), but those who quit over side effects hold out even at a $25 copay
59.1% 59.1% of past GLP-1 users would likely restart within six months at $99 a month out of pocket, against 13.8% at $349 and 72.7% with a $25 insurance copay (base 159)
Read -
GLP-1 considerers: cost holds back 70.8%, and starting only becomes likely near $49 a month
70.8% 70.8% of never-users considering a GLP-1 say the monthly cost is the one concern that most holds them back, far ahead of not being sure it is medically right (13.9%) and side effects (11.7%). (base 137)
Read
What do people ask about glp-1: starting, stopping and restarting?
- After stopping a GLP-1, what do past users turn to for keeping the weight off: a diet program, fitness, supplements or nothing?
- In November 2026, 67.5% of US past GLP-1 users said they rely most on eating less or eating differently on their own to keep the weight off after stopping (n=166), against 17.5% on exercise, 12.0% on nothing in particular and 2.4% on a structured diet program.Read the insight
- When a health plan drops GLP-1 weight-loss coverage, what do people considering the drug do instead?
- When a health plan drops GLP-1 weight-loss coverage, 65.5% of US GLP-1 considerers would turn to diet and exercise or put treatment off rather than take any medicine, and only 11.5% would pay a drug maker's $350 to $500 cash price (n=139, October 2026).Read the insight
- Why did past GLP-1 users stop, and what would bring them back?
- In October 2026, US past GLP-1 users most often said they stopped because of side effects (35.3%) or cost and lost coverage (31.2%, n=170), and the change that would bring them back matched the reason: 94.3% of cost quitters chose coverage under $50 a month and 60.0% of side-effect quitters a lower dose.Read the insight
- Would GLP-1 users switch from an injection to a daily pill at the same price, and what if the pill worked slightly less well?
- In September 2026, 37.5% of US weekly GLP-1 injection users (75 of 200, n=200) said they would be likely to switch to a once-daily pill at the same monthly price and the same weight loss, falling to 17.0% if the pill gave about 12% weight loss instead of about 15%.Read the insight
- What would make someone considering a GLP-1 weight-loss medication actually start?
- The monthly cost is the main thing holding back 70.8% of US adults considering a GLP-1 weight-loss medication who have never taken one (n=137, September 2026), and without insurance only 2.2% would be likely to start at $499 a month against 53.3% at $49.Read the insight
- Why do people stop taking a GLP-1, and what would make a past user restart?
- Among US past GLP-1 users, 59.1% say they would likely restart within six months at $99 a month out of pocket, against 13.8% at $349 and 72.7% with a $25 insurance copay (n=159, September 2026).Read the insight
Other topics
How should you read these findings?
Where the numbers come from. Every figure on this site is a predicted response from Brox clones: behavioural replicas of real people, each built from a long-form interview with that person. The base under each figure is the number of clones behind it.
Where the real data comes from. The long-form video interviews with the real people the clones are built from. A quote is always shown with the interview line it was predicted from.
What you can take away. Insights publish their tabulation as CSV and JSON: question, option, count, percentage and base. Never per-person rows.
Ask this of your own customers: humans@brox.ai